vs
Side-by-side financial comparison of Bausch Health Companies Inc. (BHC) and ON Semiconductor (ON). Click either name above to swap in a different company.
Bausch Health Companies Inc. is the larger business by last-quarter revenue ($2.8B vs $1.6B, roughly 1.8× ON Semiconductor). ON Semiconductor runs the higher net margin — 16.4% vs -3.7%, a 20.1% gap on every dollar of revenue. On growth, Bausch Health Companies Inc. posted the faster year-over-year revenue change (9.3% vs -10.0%). Bausch Health Companies Inc. produced more free cash flow last quarter ($403.0M vs $372.4M). Over the past eight quarters, Bausch Health Companies Inc.'s revenue compounded faster (14.0% CAGR vs -12.3%).
Bausch Health Companies Inc. is a global, diversified American-Canadian pharmaceutical company. Its global corporate headquarters are located in Laval, Quebec, Canada, and its U.S. headquarters are in Bridgewater, New Jersey. It develops, manufactures and markets a range of pharmaceutical products in gastroenterology, hepatology, neurology, dermatology, dentistry, medical aesthetics, and international pharmaceuticals. Bausch Health manufactures and markets branded pharmaceuticals, generic ph...
Fairchild Semiconductor International, Inc. was an American semiconductor company based in San Jose, California. It was founded in 1957 as a division of Fairchild Camera and Instrument by the "traitorous eight" who defected from Shockley Semiconductor Laboratory. It became a pioneer in the manufacturing of transistors and of integrated circuits. Schlumberger bought the firm in 1979 and sold it to National Semiconductor in 1987; Fairchild was spun off as an independent company again in 1997. I...
BHC vs ON — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.8B | $1.6B |
| Net Profit | $-103.0M | $255.0M |
| Gross Margin | — | 37.9% |
| Operating Margin | 17.0% | 17.0% |
| Net Margin | -3.7% | 16.4% |
| Revenue YoY | 9.3% | -10.0% |
| Net Profit YoY | -205.1% | -32.9% |
| EPS (diluted) | $-0.30 | $0.63 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.8B | $1.6B | ||
| Q3 25 | $2.7B | $1.5B | ||
| Q2 25 | $2.5B | $1.4B | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.6B | $1.7B | ||
| Q3 24 | $2.5B | $1.8B | ||
| Q2 24 | $2.4B | $1.7B | ||
| Q1 24 | $2.2B | $1.9B |
| Q4 25 | $-103.0M | $255.0M | ||
| Q3 25 | $179.0M | $170.3M | ||
| Q2 25 | $148.0M | $-486.1M | ||
| Q1 25 | $-58.0M | — | ||
| Q4 24 | $98.0M | $379.9M | ||
| Q3 24 | $-85.0M | $401.7M | ||
| Q2 24 | $10.0M | $338.2M | ||
| Q1 24 | $-64.0M | $453.0M |
| Q4 25 | — | 37.9% | ||
| Q3 25 | — | 37.6% | ||
| Q2 25 | — | 20.3% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 45.2% | ||
| Q3 24 | — | 45.4% | ||
| Q2 24 | — | 45.2% | ||
| Q1 24 | — | 45.8% |
| Q4 25 | 17.0% | 17.0% | ||
| Q3 25 | 23.1% | 13.2% | ||
| Q2 25 | 17.5% | -39.7% | ||
| Q1 25 | 12.2% | — | ||
| Q4 24 | 21.8% | 23.7% | ||
| Q3 24 | 12.7% | 25.3% | ||
| Q2 24 | 16.2% | 22.4% | ||
| Q1 24 | 13.1% | 28.2% |
| Q4 25 | -3.7% | 16.4% | ||
| Q3 25 | 6.7% | 11.6% | ||
| Q2 25 | 5.8% | -33.6% | ||
| Q1 25 | -2.6% | — | ||
| Q4 24 | 3.8% | 22.1% | ||
| Q3 24 | -3.4% | 22.8% | ||
| Q2 24 | 0.4% | 19.5% | ||
| Q1 24 | -3.0% | 24.3% |
| Q4 25 | $-0.30 | $0.63 | ||
| Q3 25 | $0.48 | $0.41 | ||
| Q2 25 | $0.40 | $-1.15 | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $0.24 | $0.88 | ||
| Q3 24 | $-0.23 | $0.93 | ||
| Q2 24 | $0.03 | $0.78 | ||
| Q1 24 | $-0.17 | $1.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $2.9B |
| Total DebtLower is stronger | $20.8B | $3.4B |
| Stockholders' EquityBook value | $-554.0M | $7.9B |
| Total Assets | $26.4B | $13.0B |
| Debt / EquityLower = less leverage | — | 0.43× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $2.9B | ||
| Q3 25 | $1.3B | $2.8B | ||
| Q2 25 | $1.7B | $3.0B | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | $719.0M | $2.8B | ||
| Q2 24 | $595.0M | $2.7B | ||
| Q1 24 | $733.0M | $2.6B |
| Q4 25 | $20.8B | $3.4B | ||
| Q3 25 | $21.0B | $3.4B | ||
| Q2 25 | $21.7B | $3.4B | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | $3.4B | ||
| Q3 24 | $21.5B | $3.4B | ||
| Q2 24 | $21.7B | $3.4B | ||
| Q1 24 | $22.1B | $3.4B |
| Q4 25 | $-554.0M | $7.9B | ||
| Q3 25 | $-565.0M | $7.9B | ||
| Q2 25 | $-764.0M | $8.0B | ||
| Q1 25 | $-1.2B | — | ||
| Q4 24 | $-1.3B | $8.8B | ||
| Q3 24 | $-1.2B | $8.6B | ||
| Q2 24 | $-1.2B | $8.3B | ||
| Q1 24 | $-1.1B | $8.1B |
| Q4 25 | $26.4B | $13.0B | ||
| Q3 25 | $26.8B | $13.1B | ||
| Q2 25 | $27.3B | $13.3B | ||
| Q1 25 | $26.4B | — | ||
| Q4 24 | $26.5B | $14.1B | ||
| Q3 24 | $26.5B | $13.9B | ||
| Q2 24 | $26.5B | $13.7B | ||
| Q1 24 | $26.9B | $13.5B |
| Q4 25 | — | 0.43× | ||
| Q3 25 | — | 0.43× | ||
| Q2 25 | — | 0.42× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.41× | ||
| Q1 24 | — | 0.42× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $495.0M | $418.7M |
| Free Cash FlowOCF − Capex | $403.0M | $372.4M |
| FCF MarginFCF / Revenue | 14.4% | 24.0% |
| Capex IntensityCapex / Revenue | 3.3% | 3.0% |
| Cash ConversionOCF / Net Profit | — | 1.64× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $1.4B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $495.0M | $418.7M | ||
| Q3 25 | $405.0M | $184.3M | ||
| Q2 25 | $289.0M | $602.3M | ||
| Q1 25 | $211.0M | — | ||
| Q4 24 | $601.0M | $579.7M | ||
| Q3 24 | $405.0M | $465.8M | ||
| Q2 24 | $380.0M | $362.2M | ||
| Q1 24 | $211.0M | $498.7M |
| Q4 25 | $403.0M | $372.4M | ||
| Q3 25 | $314.0M | $106.1M | ||
| Q2 25 | $190.0M | $454.7M | ||
| Q1 25 | $96.0M | — | ||
| Q4 24 | $495.0M | $434.8M | ||
| Q3 24 | $334.0M | $293.6M | ||
| Q2 24 | $302.0M | $207.7M | ||
| Q1 24 | $129.0M | $276.3M |
| Q4 25 | 14.4% | 24.0% | ||
| Q3 25 | 11.7% | 7.2% | ||
| Q2 25 | 7.5% | 31.5% | ||
| Q1 25 | 4.2% | — | ||
| Q4 24 | 19.3% | 25.2% | ||
| Q3 24 | 13.3% | 16.7% | ||
| Q2 24 | 12.6% | 12.0% | ||
| Q1 24 | 6.0% | 14.8% |
| Q4 25 | 3.3% | 3.0% | ||
| Q3 25 | 3.4% | 5.3% | ||
| Q2 25 | 3.9% | 10.2% | ||
| Q1 25 | 5.1% | — | ||
| Q4 24 | 4.1% | 8.4% | ||
| Q3 24 | 2.8% | 9.8% | ||
| Q2 24 | 3.2% | 8.9% | ||
| Q1 24 | 3.8% | 11.9% |
| Q4 25 | — | 1.64× | ||
| Q3 25 | 2.26× | 1.08× | ||
| Q2 25 | 1.95× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 6.13× | 1.53× | ||
| Q3 24 | — | 1.16× | ||
| Q2 24 | 38.00× | 1.07× | ||
| Q1 24 | — | 1.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
ON
| Industrial Segment | $426.3M | 27% |
| Other End Markets Segment | $337.3M | 22% |
| Intelligent Sensing Segments | $284.0M | 18% |
| Direct Customers | $282.4M | 18% |
| Intelligent Sensing Group | $230.0M | 15% |
